Viatris to Acquire Pacira BioSciences for $1.65B in Pain Portfolio Expansion

Viatris announced a $1.65 billion acquisition of Pacira BioSciences, a specialty pain medication maker, expanding its portfolio. The deal is a strategic consolidation in the pharmaceutical sector, likely to face regulatory review. Financial terms and expected synergies remain undisclosed, but the move signals continued M&A activity in healthcare.